Trial Profile
Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics
- Acronyms OPTIMA
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 13 Feb 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Mar 2017.